SEC Form 4 · accession 0001193125-26-295112
NEKTAR THERAPEUTICS · NKTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan Zalevsky
Officer — Chief R&D Officer
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 7:06 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000906709
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 30, 2026 | S | 5,681 | $70.00 | D | 9,756 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.